LYEL - Lyell Immunopharma, Inc. Stock Price, Fair Value and News

$1.02-0.09 (-8.11%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LYEL Price Action

Last 7 days

-7.3%

Last 30 days

-8.9%

Last 90 days

-29.7%

Trailing 12 Months

-42.0%

LYEL RSI Chart

LYEL Valuation

Market Cap

284.8M

Price/Earnings (Trailing)

-1.4

Price/Sales (Trailing)

2.6K

Price/Free Cashflow

-1.82

LYEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LYEL Fundamentals

LYEL Revenue

Revenue (TTM)

130.0K

Rev. Growth (Yr)

36%

Rev. Growth (Qtr)

161.54%

LYEL Earnings

Earnings (TTM)

-204.0M

Earnings Growth (Yr)

12.33%

Earnings Growth (Qtr)

2.68%

LYEL Profitability

Return on Equity

-38.44%

Return on Assets

-32.94%

Free Cashflow Yield

-54.86%

LYEL Investor Care

Shares Dilution (1Y)

10.86%

Diluted EPS (TTM)

-0.79

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	63.5M	42.4M	21.3M	130.0K
2022	29.2M	47.7M	66.2M	84.7M
2021	8.9M	8.5M	10.0M	10.7M
2020	0	3.0M	5.4M	7.8M
2019	0	0	0	657.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

CEO	Dr. Lynn Seely M.D., Ph.D.
WEBSITE	lyell.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	274

Lyell Immunopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Lyell Immunopharma, Inc.? What does LYEL stand for in stocks?

LYEL is the stock ticker symbol of Lyell Immunopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lyell Immunopharma, Inc. (LYEL)?

As of Wed Nov 20 2024, market cap of Lyell Immunopharma, Inc. is 284.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LYEL stock?

You can check LYEL's fair value in chart for subscribers.

Is Lyell Immunopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether LYEL is over valued or under valued. Whether Lyell Immunopharma, Inc. is cheap or expensive depends on the assumptions which impact Lyell Immunopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYEL.

What is Lyell Immunopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, LYEL's PE ratio (Price to Earnings) is -1.4 and Price to Sales (PS) ratio is 2.6 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYEL PE ratio will change depending on the future growth rate expectations of investors.